Priming of naive T cells inside tumors leads to eradication of established tumors

Nature Immunology

Volumn 5, Issue 2, 2004, Pages 141-149

  Yu, Ping ^a   Lee, Youjin ^a   Liu, Wenhua ^a   Chin, Robert K ^a   Wang, Jing ^a   Wang, Yang ^a   Schietinger, Andrea ^a   Philip, Mary ^a   Schreiber, Hans ^a   Fu, Yang Xin ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CELL ADHESION MOLECULE; CHEMOKINE; LYMPHOTOXIN BETA; PROTEIN LIGHT; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR; TUMOR VACCINE; UNCLASSIFIED DRUG;

ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOPATHOLOGY; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE DEPLETION; LYMPHOCYTE HOMING; LYMPHOCYTE SUBPOPULATION; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; TUMOR CELL LINE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR REJECTION; UPREGULATION;

ANIMALS; CELL ADHESION MOLECULES; CHEMOKINES; FEMALE; GENE EXPRESSION; GRAFT REJECTION; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MEMBRANE PROTEINS; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MODELS, IMMUNOLOGICAL; NEOPLASM TRANSPLANTATION; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 14; RECEPTORS, VIRUS; SARCOMA, EXPERIMENTAL; T-LYMPHOCYTES; TRANSDUCTION, GENETIC; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 14; TUMOR NECROSIS FACTOR-ALPHA; VACCINATION;

EID: 10744227434     PISSN: 15292908     EISSN: None     Source Type: Journal    
DOI: 10.1038/ni1029     Document Type: Article

References (49)

1. Boon, T. & van der Bruggen, P. Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 183, 725-729 (1996).
2. Rosenberg, S.A. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 10, 281-287 (1999).
3. Groh, V., Wu, J., Yee, C. & Spies, T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419, 734-738 (2002).
4. Berzofsky, J.A., Ahlers, J.D. & Belyakov, I.M. Strategies for designing and optimizing new generation vaccines. Nat. Rev. Immunol. 1, 209-219 (2001).
5. Pardoll, D.M. Spinning molecular immunology into successful immunotherapy. Nat. Rev. Immunol. 2, 227-238 (2002).
6. Chambers, C.A., Kuhns, M.S., Egen, J.G. & Allison, J.P. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu. Rev. Immunol. 19, 565-594 (2001).
7. Terabe, M. et al. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat. Immunol. 1, 515-520 (2000).
8. Ochsenbein, A.F. et al. Immune surveillance against a solid tumor fails because of immunological ignorance. Proc. Natl. Acad. Sci. USA 96, 2233-2238 (1999).
9. Singh, S., Ross, S.R., Acena, M., Rowley, D.A. & Schreiber, H. Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells. J. Exp. Med. 175, 139-146 (1992).
10. Perdrizet, G.A. et al. Animals bearing malignant grafts reject normal grafts that express through gene transfer the same antigen. J. Exp. Med. 171, 1205-1220 (1990).
11. Sarma, S. et al. Cytotoxic T lymphocytes to an unmutated tumor rejection antigen P1A: normal development but restrained effector function in vivo. J. Exp. Med. 189, 811-820 (1999).
12. Wick, M. et al. Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J. Exp. Med. 186, 229-238 (1997).
13. + T cell adoptive immunotherapy. Immunity 13, 265-276 (2000).
14. Dudley, M.E. et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298, 850-854 (2002).
15. Rosenberg, S.A. Progress in the development of immunotherapy for the treatment of patients with cancer. J. Intern. Med. 250, 462-475 (2001).
16. Lee, K.H. et al. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J. Immunol. 163, 6292-6300 (1999).
17. Mauri, D.N. et al. LIGHT, a new member of the TNF superfamily, and lymphotoxin α are ligands for herpesvirus entry mediator. Immunity 8, 21-30 (1998).
18. Ngo, V.N. et al. Lymphotoxin α/β and tumor necrosis factor are required for stromal cell expression of homing chemokines in B and T cell areas of the spleen. J. Exp. Med. 189, 403-412 (1999).
19. Wang, J. et al. The complementation of lymphotoxin deficiency with LIGHT, a newly discovered TNF family member, for the restoration of secondary lymphoid structure and function. Eur. J. Immunol. 32, 1969-1979 (2002).
20. Ueno, T. et al. Role for CCR7 ligands in the emigration of newly generated T lymphocytes from the neonatal thymus. Immunity 16, 205-218 (2002).
21. Gunn, M.D. et al. Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization. J. Exp. Med. 189, 451-460 (1999).
22. Tamada, K. et al. Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway. Nat. Med. 6, 283-289 (2000).
23. Dranoff, G. et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 90, 3539-3543 (1993).
24. Lenschow, D.J., Walunas, T.L. & Bluestone, J.A. CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. 14, 233-258 (1996).
25. Chen, L. et al. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J. Exp. Med. 179, 523-532 (1994).
26. Montgomery, R.I., Warner, M.S., Lum, B.J. & Spear, P.G. Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family. Cell 87, 427-436 (1996).
27. Kwon, B.S. et al. A newly identified member of the tumor necrosis factor receptor superfamily with a wide tissue distribution and involvement in lymphocyte activation. J. Biol. Chem. 272, 14272-14276 (1997).
28. Harrop, J.A. et al. Antibodies to TR2 (herpesvirus entry mediator), a new member of the TNF receptor superfamily, block T cell proliferation, expression of activation markers, and production of cytokines. J. Immunol. 161, 1786-1794 (1998).
29. Fu, Y.X. & Chaplin, D.D. Development and maturation of secondary lymphoid tissues. Annu. Rev. Immunol. 17, 399-433 (1999).
30. Cyster, J.G. Chemokines and cell migration in secondary lymphoid organs. Science 286, 2098-2102 (1999).
31. Farber, J.M. Mig and IP-10: CXC chemokines that target lymphocytes. J. Leukoc. Biol. 61, 246-257 (1997).
32. Kang, H.S. et al. Signaling via LTβR on the lamina propria stromal cells of the gut is required for IgA production. Nat. Immunol. 3, 576-582 (2002).
33. + T cells. J. Exp. Med. 197, 985-995 (2003).
34. + T cell subsets. Nat. Immunol. 4, 225-234 (2003).
35. Chen, L. Immunological ignorance of silent antigens as an explanation of tumor evasion. Immunol. Today 19, 27-30 (1998).
36. Ochsenbein, A.F. et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 411, 1058-1064 (2001).
37. Spiotto, M.T. et al. Increasing tumor antigen expression overcomes 'ignorance' to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity 17, 737-747 (2002).
38. Schrama, D. et al. Targeting of lymphotoxin-α to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue. Immunity 14, 111-121 (2001).
39. Sharma, S. et al. Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J. Immunol. 164, 4558-4563 (2000).
40. Bai, X.F. et al. On the site and mode of antigen presentation for the initiation of clonal expansion of CD8 T cells specific for a natural tumor antigen. Cancer Res, 61, 6860-6867 (2001).
41. Wang, J. et al. The regulation of T cell homeostasis and autoimmunity by T cell-derived LIGHT. J. Clin. Invest. 108, 1771-1780 (2001).
42. Sharma, S. et al. SLC/CCL21-mediated antitumor responses require IFNγ, MIG/CXCL9 and IP-10/CXCL10. Mol. Cancer 2, 22 (2003).
43. Zhai, Y. et al. LIGHT, a novel ligand for lymphotoxin β receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer. J. Clin. Invest. 102, 1142-1151 (1998).
44. Harrop, J.A. et al. Herpesvirus entry mediator ligand (HVEM-L), a novel ligand for HVEM/TR2, stimulates proliferation of T cells and inhibits HT29 cell growth. J. Biol. Chem. 273, 27548-27556 (1998).
45. Browning, J.L. et al. Signaling through the lymphotoxin β receptor induces the death of some adenocarcinoma tumor lines. J. Exp. Med. 183, 867-878 (1996).
46. Ward, P.L., Koeppen, H., Hurteau, T. & Schreiber, H. Tumor antigens defined by cloned immunological probes are highly polymorphic and are not detected on autologous normal cells. J. Exp. Med. 170, 217-232 (1989).
47. Yu, P. et al. B cells control the migration of a subset of dendritic cells into B cell follicles via CXC chemokine ligand 13 in a lymphotoxin-dependent fashion. J. Immunol. 168, 5117-5123 (2002).
48. Wu, Q. et al. The requirement of membrane lymphotoxin for the presence of dendritic cells in lymphoid tissues. J. Exp. Med. 190, 629-638 (1999).
49. Hathcock, K.S. T cell depletion by cytotoxic elimination. in Current Protocols in Immunology (Coligan, J.E. et al.) 3.4.1-3.4.3 (Wiley, New York, 1991).